Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease

J Mol Neurosci. 2010 May;41(1):110-3. doi: 10.1007/s12031-009-9297-1. Epub 2009 Oct 16.

Abstract

We previously reported that coenzyme Q10 (CoQ10) could reduce intracellular deposition in an aged transgenic mouse model. Here, we further tested the effect of CoQ10 on amyloid plaque in an amyloid precursor protein/presenilin 1 transgenic mouse model of Alzheimer's disease (AD). By using immunohistochemistry and magnetic resonance imaging to determine the burden of amyloid plaque, we found that oral administration of CoQ10 can efficiently reduce the burden of the plaques in this mouse model. These data demonstrate that in addition to reducing intracellular deposition of Abeta, CoQ10 can also reduce plaque pathology. Our study further supports the use of CoQ10 as a therapeutic candidate for AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / pathology
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / pathology
  • Disease Models, Animal
  • Hippocampus / drug effects
  • Hippocampus / pathology
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Mice
  • Mice, Transgenic
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Plaque, Amyloid / drug effects*
  • Plaque, Amyloid / pathology
  • Presenilin-1 / metabolism*
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / pharmacology
  • Ubiquinone / therapeutic use
  • Vitamins* / pharmacology
  • Vitamins* / therapeutic use

Substances

  • Amyloid beta-Peptides
  • Neuroprotective Agents
  • Presenilin-1
  • Vitamins
  • Ubiquinone
  • coenzyme Q10